Overview
The India‑U.K. Comprehensive Economic and Trade Agreement (CETA) came into force on 15 July 2026. It removes tariffs on about 99% of Indian exports and eases mobility for certain professionals. However, three critical areas – investment protection, pharmaceutical patent standards, and a carbon‑border levy – remain outside the pact.
Key Developments
- Tariff elimination on 99% of Indian goods, but no dedicated BIT provision in CETA.
- India retains Section 3(d) of its patent law, limiting U.K. pharma access.
- The U.K. will introduce the CBAM from 1 January 2027, separate from CETA.
- Former Commerce Minister Piyush Goyal has warned that the deal omits contentious issues.
Important Facts
1. Investment protection: Unlike India’s deals with the European Free Trade Association and New Zealand, CETA lacks a clause that obliges the U.K. to facilitate a set amount of investment in India. The stalemate stems from differing views on arbitration – India cancelled most of its BITs in 2017 to bring disputes under its domestic courts first.
2. Pharma market access: The U.K. exports about £26 billion of medicines worldwide, but only £127 million (0.5%) go to India. Retaining Section 3(d) means Indian generic manufacturers can produce cheaper versions once the original patent expires, keeping U.K. firms from dominating the market.
3. Carbon cost: Even with lower tariffs, Indian steel and aluminium exporters may face a CBAM charge that mirrors the carbon price paid by U.K. producers. No exemption has been granted yet, so the net benefit of CETA could be eroded after 2027.
Exam Relevance
Understanding CETA touches on multiple GS papers. GS3 candidates must analyse the trade‑off between tariff reductions and missing investment safeguards.